4.7 Article

Hyaluronan-based theranostic nanomicelles for breast cancer-targeting and anticancer drug delivery

期刊

MATERIALS & DESIGN
卷 225, 期 -, 页码 -

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.matdes.2022.111551

关键词

Hyaluronan; Nanomicelles; Drug delivery; SPECT; CT imaging; Curcumin

向作者/读者索取更多资源

Integration of diagnostic and therapeutic modalities into a single nanoplatform (HPCT nanomicelles) for breast cancer was achieved in this study. The nanomicelles comprised hyaluronan-b-poly(ecaprolactone) (HA-PCL), curcumin (Cur), and tocopheryl polyethylene glycol succinate (TPGS). Efficient drug loading, stability, and hyaluronidase-sensitive release were observed in the HPCT nanomicelles. In vivo SPECT/CT imaging confirmed the active targeting ability of the HAbased nanomicelles to breast cancer, while pharmacodynamic studies showed desirable anti-tumor efficacy with good biosafety. The 99mTc-HPCT nanomicelles, integrating imaging and therapeutic modalities, have great potential as an all-in-one theranostic nanoplatform for breast cancer.
Integration of diagnostic and therapeutic modalities into a single nanoplatform can play an important role in personalized cancer therapy. In this work, an all-in-one theranostic nanoplatform (HPCT nanomicelles) for breast cancer was fabricated, composed of the synthetic polymer hyaluronan-b-poly(ecaprolactone) (HA-PCL), drug curcumin (Cur) and adjuvant tocopheryl polyethylene glycol succinate (TPGS). HPCT nanomicelles presented adequate drug loading efficiency, excellent stability, and attractive hyaluronidase-sensitive release features. Imaging agent radionuclide 99mTc was loaded into HPCT nanomicelles (denoted as 99mTc-HPCT nanomicelles) and in vivo SPECT/CT imaging verified the HAbased nanomicelles could actively target breast cancer in mice. In vivo anti-tumor pharmacodynamic studies indicated that HPCT nanomicelles exhibited desirable anti-tumor efficacy with favorable biosafety. 99mTc-HPCT nanomicelles, integrating imaging and therapeutic modalities, have the promising potential to be an all-in-one theranostic nanoplatform for breast cancer.& COPY; 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据